0000000001102537

AUTHOR

Lena Dillner

showing 3 related works from this author

European code against cancer 4th edition: 12 ways to reduce your cancer risk

2015

AbstractThis overview describes the principles of the 4th edition of the European Code against Cancer and provides an introduction to the 12 recommendations to reduce cancer risk. Among the 504.6 million inhabitants of the member states of the European Union (EU28), there are annually 2.64 million new cancer cases and 1.28 million deaths from cancer. It is estimated that this cancer burden could be reduced by up to one half if scientific knowledge on causes of cancer could be translated into successful prevention. The Code is a preventive tool aimed to reduce the cancer burden by informing people how to avoid or reduce carcinogenic exposures, adopt behaviours to reduce the cancer risk, or t…

Cancer Researchmedicine.medical_specialtyQuality Assurance Health CareEpidemiologyUterine Cervical NeoplasmsCancer preventionCauses of cancerCancer screeningBreast cancerRisk FactorsEnvironmental healthCancer screeningmedicinemedia_common.cataloged_instanceHumansEuropean UnionEuropean unionPreventive healthcaremedia_commonCervical cancerCancer risk factorsCancer preventionbusiness.industryCancermedicine.diseaseEuropeOncology1117 Public Health And Health ServicesWorking Groups of Scientific ExpertsPractice Guidelines as TopicFemalebusiness1112 Oncology And Carcinogenesis
researchProduct

Human papillomavirus antibody responses among patients with incident cervical carcinoma

1997

The human papillomavirus (HPV) is recognized as a major cause of cervical cancer precursor lesions. HPV serology is a key method in the continuing elucidation of the importance of HPV exposure for cancer development and in predicting HPV-associated diseases. To extend previous HPV serological studies on cervical cancer, serum samples from a consecutive series of 216 women with incident untreated cervical carcinoma and 243 age- and sex-matched healthy blood donors were evaluated for the presence of antibodies against HPV capsids, a marker of past or present HPV exposure, as well as against several cervical cancer-associated defined HPV epitopes. Among the capsid antibody responses, HPV type …

AdultMolecular Sequence DataUterine Cervical NeoplasmsAntibodies ViralKlinikai orvostudományokEpitopeSerologyEpitopesCapsidRisk FactorsVirologyCarcinomamedicineHumansAmino Acid SequenceRisk factorAntigens ViralPapillomaviridaeAgedAged 80 and overCervical cancerbiologybusiness.industryPapillomavirus Infectionsvirus diseasesOrvostudományokMiddle Agedmedicine.diseaseVirologyfemale genital diseases and pregnancy complicationsTumor Virus InfectionsInfectious DiseasesCase-Control StudiesImmunologybiology.proteinFemaleHuman Papillomavirus AntibodyViral diseaseAntibodybusiness
researchProduct

A survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children.

1999

The importance and natural history of HPV infections in childhood is incompletely understood. We performed a survey for presence of serum antibodies to HPV capsids among 1031 children aged 0 to 13 years, resident in Stockholm, Sweden. The HPV seroprevalence among these children was 3.0% for HPV16, 0.6% for HPV18 and 2.7% for HPV33. By comparison, among simultaneously analyzed positive control panels comprising women with CIN or healthy women with type-specific cervical HPV DNA, seroprevalence of HPV 16, 18 and 33 was 69%, 58% and 63% respectively. The results suggest that HPV infection in childhood is not common.

Cancer Researchmedicine.medical_specialtyAdolescentvirusesAntibodies ViralSerologyCapsidInternal medicineEpidemiologymedicineSeroprevalenceHumansChildPapillomaviridaeSwedenbusiness.industryPublic healthPapillomavirus InfectionsHPV infectionInfant Newbornvirus diseasesInfantmedicine.diseasefemale genital diseases and pregnancy complicationsNatural historyTumor Virus InfectionsOncologyEl NiñoChild PreschoolImmunologyFemaleViral diseasebusinessInternational journal of cancer
researchProduct